Molina, Abarca partner to use analytics to aid medication management

Molina Healthcare of Puerto Rico and Abarca are partnering to bring predictive analytics to medication therapy management for Molina’s high-cost and most vulnerable members.

Under the two-year agreement, San Juan-based Abarca—a pharmacy benefit manager and technology company—will offer MTM services to the members of Molina Healthcare of Puerto Rico, a locally operated subsidiary of Molina Healthcare.

The initiative will use Abarca's cloud-based application, Darwin RxTarget, a predictive analytics tool that will identify members who need help with managing access to their medication and medication adherence.

puerto-rico-la-fortaleza-bl070715-357.jpg

The Darwin RxTarget will provide Molina with a customizable dashboard that incorporates proprietary clinical decision-making algorithms and a tailored view of beneficiaries and prescribers in real time. The module also will focus on key quality measures to improve access to preventive care, Abarca said.

"Molina is always exploring ways to improve the overall health and well-being of our members, and this partnership allows us to accomplish that by increasing access to care and educating those we serve," says Carlos Carrero, president of Molina Healthcare of Puerto Rico. "We are committed to improving the health of our members across the Island and are equally focused on ensuring each one has an appropriate care plan and the support they need."

Molina Healthcare of Puerto Rico, with regional offices in Humacao, Ponce, and Yauco, has been providing government-funded care for low-income individuals since 2015—serving members through the government's health program.

Under the new MTM program, Molina will target members who:

  • Suffer from at least two chronic medical conditions or one high-cost condition, such as rheumatoid arthritis, multiple sclerosis or end-stage renal disease.
  • Are taking more than three chronic medications simultaneously.
  • Are expected to spend at least $2,000 on chronic medications annually.

The program is expected to help improve medication adherence for people suffering from diabetes, high cholesterol, hypertension, depression, rheumatoid arthritis and other chronic conditions. Additionally, the program includes targeted safeguards to reduce opioid overutilization, according to Molina. The program will also enable Molina's members to comply with higher generic dispensing rates and increase adherence to formulary drugs.

"When it comes to helping Molina increase medication access and adherence for its members, we are all in

"Darwin RxTarget is just one of the advanced clinical modules that can be licensed individually from Darwin," says Jason Borschow, president and CEO of Abarca. “By leveraging this … technology, and a strong collaboration with our partners, we are finding new, highly targeted and effective approaches to improving health outcomes."

For reprint and licensing requests for this article, click here.